Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05773846
Other study ID # PRF-110-103
Secondary ID
Status Recruiting
Phase Phase 3
First received
Last updated
Start date March 13, 2023
Est. completion date January 30, 2024

Study information

Verified date December 2023
Source PainReform LTD
Contact Sigal Aviel, PhD
Phone +972- 3-7177053
Email saviel@painreform.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

PRF-110 is a viscous, yellowish clear oily solution of ropivacaine intended for administration into surgical sites to provide post-operative analgesia. The pharmacokinetic profile for PRF-110 suggests that its effect could last up to 72 hours. This is A Phase 3, Randomized, Double-Blind, Saline Placebo- and Active-Controlled, Multicenter Study to Evaluate the Analgesic Efficacy and Safety of Intra-operative Administration of PRF-110 Following Unilateral Bunionectomy


Description:

PRF-110 is a unique, sustained-release, oil-based solution formulation of ropivacaine intended for administration into surgical sites for the prevention of postoperative pain. The formulation is designed to have an effect for up to 72 hours. It is postulated that PRF-110 will improve postoperative pain management by providing prolonged pain relief at the surgical site; thereby, reducing the amount of systemic analgesia needed after surgery. The slow, local release of ropivacaine following administration of PRF-110 has been demonstrated in dissolution studies, in postoperative pain studies in animals, in an experimental pain study in human volunteers, and in an open-label Phase 2 hernia repair trial to result in very low plasma concentrations of drug, therefore reducing the probability of systemic adverse events. This is a randomized, double-blind study to evaluate the efficacy and safety of PRF-110 compared with saline placebo and with ropivacaine hydrochloride injection administered intraoperatively in subjects undergoing unilateral bunionectomy.


Recruitment information / eligibility

Status Recruiting
Enrollment 415
Est. completion date January 30, 2024
Est. primary completion date December 30, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: Inclusion criteria: Subjects must meet all of the following criteria to be eligible for inclusion into the study: 1. Able to provide written informed consent prior to any study procedures. 2. Able to communicate clearly with the Investigators and study staff. 3. Males and females aged 18 years or older. 4. Scheduled for elective primary unilateral first metatarsal bunionectomy surgery (osteotomy and internal fixation) with no ancillary procedures. 5. Female subjects must be surgically sterile; or at least 2 years postmenopausal; or have a monogamous partner who is surgically sterile; or practicing doublebarrier contraception; or practicing abstinence (must agree to use double-barrier contraception in the event of sexual activity); or using an insertable, injectable, transdermal, or combination oral contraceptive approved by the FDA for greater than two months prior to screening and commit to the use of an acceptable form of birth control for the duration of the study and for 30 days after completion of the study. 6. Negative alcohol breath/saliva test and urine drug screen for drugs of abuse at Screening and at Baseline. Subjects with positive results on the alcohol breath/saliva test or urine drug screen at Screening, and/or prior to surgery, will not be allowed to proceed in the study unless the results can be explained by a current prescription or acceptable over-the-counter medication as determined by the Investigator. Note that for those subjects who test positive for tetrahydrocannabinol (THC), if they are willing to abstain from use or consumption of THC-containing products from Screening thru last Follow-up Visit, they may be allowed to participate in the study. 7. American Society of Anesthesiologists (ASA) Physical Status of I or II (see Appendix, Section 14.1). 8. Body Mass Index (BMI) =35. Exclusion Criteria: subject will be excluded from the study if any of the following criteria are met: 1. Has clinically significant allergies to an opioid, unless has subsequently tolerated other opioids and, in the opinion of the Investigator, could tolerate a rescue drug containing oxycodone. 2. Has a known or suspected allergy to any local anesthetic or to acetaminophen. 3. Has a known or suspected history of alcohol, opiate or other drug abuse or dependence within 12 months prior to screening. 4. Is unable to refrain from alcohol consumption for a period beginning 24 hours prior to surgery through the end of the 72 -hour evaluation period. 5. Has taken any analgesic or non-opioid pain medication other than acetaminophen (e.g., NSAIDs, cyclooxygenase-2 [COX 2] inhibitors) within 12 hours prior to surgery or any aspirin-containing product within 7 days of the Baseline assessments. Aspirin up to 325 mg once daily for cardiovascular prophylaxis is allowed. 6. Has taken any opioid analgesics or used systemic steroids within 4 days of surgery. 7. Has been using opiates or any non-steroidal anti-inflammatory drug chronically (more than 10 consecutive days) anytime over the past 3 months. 8. Has used antipsychotics or antiepileptics within 30 days prior to surgery. Use of sedatives, hypnotics, antianxiety agents, and antidepressants (other than monoamine oxidase inhibitors [MAOIs]) are allowed if being used for a nonpain indication and at a stable dose within the previous 30 days. 9. Has history of or positive test results for HIV or hepatitis B or C at Screening. 10. Has any history of epilepsy, other than childhood febrile seizures, before the age of 6. 11. Has any history of psychosis, current clinically significant symptomatic psychiatric disorder, or a history of suicide attempt in the past 10 years. 12. Has taken herbal agents or nutraceuticals (e.g., chapparal, comfrey, germander, jin bu huan, kava, pennyroyal, skullcap, St. John's wort, or valerian) during any of the 7 days prior to surgery that could potentially confound the analgesic response in the Investigator's opinion. 13. Has transaminase levels > 2 x ULN, or bilirubin level > 1.5 x ULN (unless Gilbert's syndrome), or estimated glomerular filtration rate (eGFR) < 60 mL/min. Has poorly controlled diabetes with hemoglobin A1c >7.5%. 15. Has any clinically significant condition including an acute or chronic painful physical restrictive condition or any other significant laboratory abnormality that would, in the opinion of the Investigator, confound study assessments or adversely affect subject safety. 16. Has received another investigational drug within 30 days of scheduled surgery.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Ropivacaine
A long acting formulation of ropivacaine

Locations

Country Name City State
United States First Surgical Hospital 4801 Bissonnet Street Bellaire Texas
United States Legent Orthopedic Hopital Carrollton Texas
United States Midwest Clinical Research Center Dayton Ohio
United States Memorial Hermann Hospital Houston Texas
United States Woodland International Research Group Little Rock Arkansas
United States Clinical Pharmacology of Miami Miami Florida
United States Endeavor Clinical Trials San Antonio Texas

Sponsors (2)

Lead Sponsor Collaborator
PainReform LTD Lotus Clinical Research, LLC

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Measurement of patients pain levels as an indication for the analgesic efficacy of PRF-110 The primary objective of this study is to compare the analgesic efficacy of PRF-110 with placebo during the first 72 hours after completion of bunionectomy surgery by measuring pain levels using an 11-point Numerical Rating Scale (NRS) 72 hours
Secondary Measurement of patients pain levels of PRF-110 as compared to ropivacaine hydrochloride Measurement of patients pain levels using an 11-point NRS in order to compare the analgesic efficacy of PRF-110 with ropivacaine hydrochloride (0=no pain and 10=worst pain imaginable) (0.5%) injection administered as an infiltration analgesic during the first 72 hours after completion of bunionectomy surgery. 72 hours
Secondary Comparison of opiate use to saline placebo To compare post-surgery opioid consumption (in morphine milligram equivalents) over 72 hours for PRF-110 with that of saline placebo. 72 hours
Secondary Comparison of opiate use to ropivacaine HCL injection To compare post-surgery opioid consumption through 72 hours for PRF-110 with that of ropivacaine injection. 72 hours
Secondary Percentage of opiate free subjects To compare the percentage of subjects who were opioid free through 72 hours post-surgery for PRF-110 compared with that of ropivacaine injection. 72 hours
See also
  Status Clinical Trial Phase
Completed NCT01435577 - Intravenous Tapentadol in Post-Bunionectomy Pain Phase 2
Terminated NCT05082012 - Early Weight-Bearing After the Lapiplasty Mini-Incision Procedure (Mini3D) N/A
Terminated NCT03257540 - Early Weight-Bearing After Lapidus Arthrodesis
Completed NCT04518462 - Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of EXPAREL, EXPAREL Admixed With Bupivacaine HCl vs. Bupivacaine HCl Administered as Combined Sciatic and Saphenous Nerve Blocks for Postsurgical Analgesia in Subjects Undergoing Lower Extremity Surgeries Phase 3
Completed NCT04084262 - Multi-Plane Hallux Valgus Correction With the Phantom® Nail
Active, not recruiting NCT03740282 - Early Weight-Bearing After the Lapiplasty Procedure N/A
Completed NCT01743625 - Safety and Efficacy Study of COV155 for Post-operative Bunionectomy Pain Phase 3
Completed NCT01484652 - Safety and Efficacy of COV795 in Moderate to Severe Post-Operative Bunionectomy Pain With an Open-label Extension Phase 3
Recruiting NCT05831449 - CPL-01 in the Management of Postoperative Pain After Bunionectomy Phase 3
Terminated NCT01133639 - Ketorolac Effects on Post-operative Pain and Bone Healing N/A
Completed NCT04826328 - Study to Evaluate the Safety and Tolerability of FX301 in Patients Undergoing Bunionectomy Phase 1
Completed NCT03653429 - Efficacy of Tranexamic Acid in Foot and Ankle Surgeries Phase 4
Recruiting NCT04751344 - Liposomal Bupivacaine Versus Bupivacaine Plain for Operative Pain Management of Forefoot Surgery Phase 4
Withdrawn NCT03954639 - Phase 3, Randomized, Double Blinded, Active Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of EXPAREL Admixed With Bupi vs. Bupi Only Administered as Combined Sciatic and Adductor Canal Nerve Block for Postsurgical Analgesia in Lower Extremity Surgeries Phase 3
Completed NCT04002089 - Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety, of EXPAREL Administered as Sciatic Nerve Block (In Popliteal Fossa), for Postsurgical Analgesia in Subjects Undergoing Bunionectomy Phase 1
Terminated NCT02499575 - Pericapsular Exparel for Pain Relief in Bunionectomy and Related Procedures N/A
Completed NCT00613938 - A Study to Evaluate the Effectiveness and Safety of Tapentadol (CG5503) in the Treatment of Acute Pain From Bunionectomy. Phase 3
Completed NCT03246971 - Study of Wafermineâ„¢ for Post-bunionectomy or Abdominoplasty Pain Phase 2
Completed NCT00890682 - Study of Postoperative Analgesia in Bunionectomy Phase 3
Active, not recruiting NCT05602844 - Clinical Trial on Patient-Specific-Instrumentation Assisted Lapidus Fusion for Hallux Valgus N/A